

## Inventiva to Present at the H.C. Wainwright 20<sup>th</sup> Annual Global Investment Conference

**Daix (France), August 29, 2018** – Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Frédéric Cren, Chief Executive Officer and co-founder of Inventiva, will present a corporate overview at the upcoming H.C. Wainwright 20<sup>th</sup> Annual Global Investment Conference being held on September 4-6, 2018 at The St. Regis New York hotel, New York, USA. The event details are as follows:

Date: Wednesday, September 5, 2018  
Time: 10:25 am (Eastern Time)  
Location: Room Louis XVI A (2<sup>nd</sup> floor), The St. Regis New York hotel

The presentation can be followed live via webcast and replayed at: <http://wsw.com/webcast/rrshq28/iva/>

The presentation document will be available on Inventiva’s website in the “Investors” – “Documentation” – “Investor presentations” section.

**About Inventiva:** [www.inventivapharma.com](http://www.inventivapharma.com)

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccharidosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

### Contacts

#### **Inventiva**

Frédéric Cren  
Chief Executive Officer  
[info@inventivapharma.com](mailto:info@inventivapharma.com)  
+33 3 80 44 75 00

#### **Brunswick**

Julien Trosdorf / Yannick Tetzlaff  
Media relations  
[inventiva@brunswickgroup.com](mailto:inventiva@brunswickgroup.com)  
+33 1 53 96 83 83

#### **LifeSci Advisors**

Chris Maggos  
Investor relations  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254